Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs

Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX) (“Calliditas”) today announced the appointment of Dr. Frank Bringstrup as Vice President Regulatory Affairs effective February 1, 2019. As a member of the Management Team, Frank will have a leading role in the regulatory discussions and approval process of the company’s pivotal clinical phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN).

“I am delighted to welcome Frank to the team at this exciting stage in the company’s development. The combination of his strong experience in regulatory affairs, not only with the FDA but on a broad international basis with a proven track record and experience from orphan drug development and bringing products to market will play a key role as we progress development of Nefecon through phase 3 clinical trials”, said Renée Aguiar-Lucander, CEO of Calliditas Therapeutics.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH